99 related articles for article (PubMed ID: 15180614)
1. Characterization of bone metastases in patients with renal cell cancer.
Adiga GU; Dutcher JP; Larkin M; Garl S; Koo J
BJU Int; 2004 Jun; 93(9):1237-40. PubMed ID: 15180614
[TBL] [Abstract][Full Text] [Related]
2. [The radiotherapeutic effect on bone metastases in relation to the frequency of metastases, sites of metastases and histology of the primary tumor].
Rieden K; Adolph J; Lellig U; zum Winkel K
Strahlenther Onkol; 1989 May; 165(5):380-5. PubMed ID: 2727892
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma.
Lee J; Hodgson D; Chow E; Bezjak A; Catton P; Tsuji D; O'Brien M; Danjoux C; Hayter C; Warde P; Gospodarowicz MK
Cancer; 2005 Nov; 104(9):1894-900. PubMed ID: 16177996
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy to bone has utility in multifocal metastatic renal carcinoma.
Reichel LM; Pohar S; Heiner J; Buzaianu EM; Damron TA
Clin Orthop Relat Res; 2007 Jun; 459():133-8. PubMed ID: 17438472
[TBL] [Abstract][Full Text] [Related]
6. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
[TBL] [Abstract][Full Text] [Related]
7. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
8. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention.
Kollender Y; Bickels J; Price WM; Kellar KL; Chen J; Merimsky O; Meller I; Malawer MM
J Urol; 2000 Nov; 164(5):1505-8. PubMed ID: 11025692
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of surgical treatment for bone metastatic lesion in renal cell carcinoma].
Mikami K; Nakagawa S; Sugimoto K; Nomoto T; Urano S; Nakamura T; Watanabe H
Hinyokika Kiyo; 1995 Apr; 41(4):241-4. PubMed ID: 7785552
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review].
Roemer-Becuwe C; Krakowski I; Conroy T
Bull Cancer; 2003 Dec; 90(12):1097-105. PubMed ID: 14715429
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
Migliorati CA; Schubert MM; Peterson DE; Seneda LM
Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
[TBL] [Abstract][Full Text] [Related]
13. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic.
Kirou-Mauro AM; Hird A; Wong J; Sinclair E; Barnes EA; Tsao M; Danjoux C; Chow E
J Pain Symptom Manage; 2009 Jan; 37(1):77-84. PubMed ID: 18504094
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
15. Serum gamma glutamyl-transferase is a sensitive but unspecific marker of metastatic renal cell carcinoma.
Simic T; Dragicevic D; Savic-Radojevic A; Cimbaljevic S; Tulic C; Mimic-Oka J
Int J Urol; 2007 Apr; 14(4):289-93. PubMed ID: 17470155
[TBL] [Abstract][Full Text] [Related]
16. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
Kuczyk M; Wegener G; Jonas U
Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
